Abstract 84P
Background
Tumor-specific neoantigens arising from non-synonymous mutations have become increasingly attractive targets for immunotherapies. The accurate identification and prioritization of neoantigens is crucial to design personalized therapies for each cancer patient. Putative immunogenic neoantigens are currently selected by using several peptide-HLA-I binding predictors. While HLA-I binding affinity is essential to tumor cell presentation of neoantigens, it is insufficient to determine neoantigen immunogenicity. As such, the vast majority of predicted tumor neoantigens (98%) are not immunogenic and ineffective in activating antitumor responses. To address this challenge, we propose integrating T-cell receptor (TCR) repertoire profiles of tumor infiltrating lymphocytes (TILs), a key determinant of immunogenicity, in the current neoantigen prediction workflow.
Methods
We sequenced the CDR3 regions of TCR beta chain (TCRB) repertoire in 27 colorectal cancer (CRC) patients and predicted neopeptide-TCR binding by using our previously published predictor, epiTCR and another existing tool pMTNet. We constructed a machine learning model which considers both peptide-HLA-I and peptide-TCR binding features to prioritize high quality immunogenic neoantigen candidates. We further performed ELISpot assay on autologous PBMCs from four CRC patients to experimentally validate the effectiveness of our model. Finally, we selected the highest immunogenic candidate to perform 10X single-cell sequencing to identify the potential neoantigen-specific TCRs for cell-based vaccine development.
Results
We showed that 5.5% of neopeptide candidates despite having weak HLA-I binding affinity are capable of binding to TCR at predicted rank < 2%. The integrated model achieved higher accuracy for ranking immunogenic neopeptides than the conventional NetMHCpan tool solely relying on peptide-HLA-I binding features.
Conclusions
Our study presents an efficient process to select and prioritize neoantigens exhibiting both HLA presentation and immunogenicity for personalized cancer immunotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Medical Genetics Institute.
Funding
Nexcalibur Therapeutics.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
62P - Combination of chemotherapy with endocrinal therapy as upfront treatment of metastatic breast cancer in hormone receptor- positive, HER2 -negative disease: A phase II randomised clinical trial
Presenter: Mariam Saleh
Session: Poster Display
Resources:
Abstract
63P - Efficacy and safety of eribulin plus carboplatin combination for HER2-negative metastatic breast cancer
Presenter: Mengqian Ni
Session: Poster Display
Resources:
Abstract
64P - Unmet needs following metastatic breast cancer in a middle-income Asian country
Presenter: Nirmala Bhoo-Pathy
Session: Poster Display
Resources:
Abstract
66P - Utidelone-based therapy in metastatic solid tumors after failure of standard therapies: A prospective, multicenter, single-arm trial
Presenter: Jianjun Zhang
Session: Poster Display
Resources:
Abstract
67P - Efficacy and safety of trastuzumab biosimilar in HER2+ve metastatic breast cancer: A multicenter phase III study
Presenter: krishna Mohan
Session: Poster Display
Resources:
Abstract
68P - Neratinib in combination with fulvestrant and or palbociclib can overcome endocrine resistance in HER2-low/ ER+ breast cancer
Presenter: Maryam Arshad
Session: Poster Display
Resources:
Abstract
69P - A multicenter, retrospective, real-world study of inetetamab combined with pyrotinib and vinorelbine as treatment for HER2-positive metastatic breast cancer
Presenter: Nan Jin
Session: Poster Display
Resources:
Abstract
70P - Overall survival of eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: A phase II, single-arm clinical trial
Presenter: Kenichi Inoue
Session: Poster Display
Resources:
Abstract
71P - Efficacy and safety of disitamab vedotin after trastuzumab for HER2 -positive breast cancer: A real-world data of retrospective study
Presenter: Chao Li
Session: Poster Display
Resources:
Abstract
72P - Real-world data on the efficacy of T-DM1 biosimilar for the treatment of HER2-positive metastatic breast cancer patients: Outcomes from a single center retrospective study in India
Presenter: Kaushal Patel
Session: Poster Display
Resources:
Abstract